People · Operator
Named in public records as an officer, director or promoter · active 2011–2019 · Biotechnology, Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vividion Therapeutics, Inc. | — | Biotechnology | Series D+ | $240.7M | $4.5B | 2016 |
| Verastem, Inc. | — | Pharmaceuticals | Series C | $163.2M | $3.5B | 2011 |
| aTYR PHARMA INC | — | Biotechnology | Series C | $122.1M | $1.9B | 2015 |
| Ivenix, Inc. | — | Biotechnology | Series B | $82.9M | $396.9M | 2015 |
| Cardinal Analytx, Inc. | — | Other Technology | Series B | $39.7M | $65.2M | 2017 |
John K. Clarke at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John K. Clarke on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| John K. Park | 2 | 2 |
| Mark Smith | 1 | 28 |
| JOHN DOERR | 1 | 14 |
| Ketan Patel | 1 | 10 |
| James C. Blair | 1 | 8 |
| Christoph Westphal | 1 | 8 |
| John Clarke | 1 | 8 |
| Wei Li | 1 | 7 |
| Timothy Barberich | 1 | 6 |
| Wayne B. Weisman | 1 | 5 |
| THOMAS MCKINLEY | 1 | 5 |
| John Park | 1 | 5 |
| Brandon Hull | 1 | 5 |
| Paul Brannelly | 1 | 4 |
| Ansbert K Gadicke | 1 | 4 |
| John Wu | 1 | 4 |
| Eric Rowinsky | 1 | 4 |
| Robert Forrester | 1 | 4 |
| Thomas G. McKinley | 1 | 3 |
| Kent Marquardt | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.